FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more
FibroGen Inc (FGEN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.106x
Based on the latest financial reports, FibroGen Inc (FGEN) has a cash flow conversion efficiency ratio of -0.106x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.85 Million) by net assets ($17.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
FibroGen Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how FibroGen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
FibroGen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of FibroGen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vow ASA
PINK:SSHPF
|
0.533x |
|
ATM Grupa S.A.
WAR:ATG
|
0.012x |
|
Lam Soon (Thailand) Public Company Limited
BK:LST
|
0.025x |
|
SKM Egg Products Export (India) Limited
NSE:SKMEGGPROD
|
-0.028x |
|
Escar Turizm Tasimacilik Ticaret AS
IS:ESCAR
|
0.012x |
|
Nobility Homes
OTCQX:NOBH
|
0.003x |
|
Sypris Solutions Inc
NASDAQ:SYPR
|
-0.009x |
|
GiantStep Co. Ltd.
KQ:289220
|
-0.086x |
Annual Cash Flow Conversion Efficiency for FibroGen Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of FibroGen Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-183.63 Million | $-138.00 Million | 0.751x | -61.31% |
| 2023-12-31 | $-162.20 Million | $-315.02 Million | 1.942x | -98.03% |
| 2022-12-31 | $-1.48 Million | $-145.93 Million | 98.603x | +27572.66% |
| 2021-12-31 | $229.11 Million | $-82.23 Million | -0.359x | -294.16% |
| 2020-12-31 | $441.45 Million | $81.60 Million | 0.185x | +225.75% |
| 2019-12-31 | $535.41 Million | $-78.70 Million | -0.147x | -2.02% |
| 2018-12-31 | $528.47 Million | $-76.14 Million | -0.144x | -26.17% |
| 2017-12-31 | $582.45 Million | $-66.51 Million | -0.114x | -381.33% |
| 2016-12-31 | $175.11 Million | $7.11 Million | 0.041x | +143.02% |
| 2015-12-31 | $196.82 Million | $-18.57 Million | -0.094x | -201.31% |
| 2014-12-31 | $240.68 Million | $22.41 Million | 0.093x | -61.34% |
| 2013-12-31 | $107.60 Million | $25.92 Million | 0.241x | +625.07% |
| 2012-12-31 | $122.18 Million | $-5.61 Million | -0.046x | -- |